Journal of the European Academy of Dermatology and Venereology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 9, 2024
The data that support the findings of this study are available from corresponding author upon reasonable request.
Язык: Английский
American Journal of Clinical Dermatology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 22, 2025
Язык: Английский
Процитировано
0
Journal of Clinical Medicine, Год журнала: 2025, Номер 14(5), С. 1746 - 1746
Опубликована: Март 5, 2025
Deucravacitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor, has demonstrated strong efficacy in the treatment of moderate-to-severe psoriasis. It works through an allosteric mechanism to selectively inhibit TYK2, leading suppression IL-23/Th17/IL-17 axis and reduction key pro-inflammatory cytokines such as IL-17A, IL-17F, IL-22, IL-23. This review focuses on clinical implications deucravacitinib East Asian patients, highlighting its efficacy, safety, differences outcomes compared other populations. Data from pivotal trials POETYK PSO-3 PSO-4, which included populations, robust safety profiles, often surpassing results observed global like PSO-1 PSO-2. Subgroup analyses network meta-analyses further corroborate these findings, providing comprehensive understanding therapeutic potential this demographic. Factors lower body mass index, genetic predispositions, environmental influences may contribute response. The profile is favorable, with low rates serious adverse events stable laboratory parameters. underscores need for research investigate genetic, metabolic, factors that influence outcomes, aiming optimize personalized strategies patients
Язык: Английский
Процитировано
0
Metabolites, Год журнала: 2025, Номер 15(3), С. 206 - 206
Опубликована: Март 18, 2025
Psoriatic arthritis (PsA) is a chronic inflammatory disease that extends beyond musculoskeletal and dermatologic involvement to elevate cardiometabolic risk. Emerging evidence highlights the critical role of systemic inflammation in metabolic dysregulation, accelerating insulin resistance, dyslipidemia, oxidative stress, all which contribute increased burden cardiovascular PsA. This review explores intricate interplay between mediators—such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-17 (IL-17),—adipokine imbalances, lipid metabolism abnormalities, foster endothelial dysfunction atherosclerosis. The dysregulation adipokines, including leptin, adiponectin, resistin, further perpetuates cascades, exacerbating Additionally, alterations seen PsA, particularly resistance dysfunction, not only comorbidities but also impact severity therapeutic response. Understanding these mechanistic links imperative for refining risk stratification strategies tailoring interventions. By integrating targeted immunomodulatory therapies with management, more comprehensive approach PsA treatment can be achieved. Future research must focus on elucidating shared pathways, enabling development innovative mitigate both complications
Язык: Английский
Процитировано
0
Journal of the European Academy of Dermatology and Venereology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 24, 2025
Язык: Английский
Процитировано
0
Frontiers in Nutrition, Год журнала: 2024, Номер 11
Опубликована: Окт. 2, 2024
Objective To explore the association between representative insulin resistance (IR) indices and risk of kidney stone disease in an American adult population. The IR referred to metabolic score for (METS-IR), triglyceride high-density lipoprotein cholesterol (TG/HDL-C) ratio, glucose-body mass index (TyG-BMI), visceral adiposity (VAI), homeostatic model assessment (HOMA-IR). Methods We investigated participants who joined 2015–2018 National Health Nutrition Examination Survey (NHANES) reported histories. Weighted proportions, multivariable regression analysis, restricted cubic splines were used evaluate associations stones after their adjustment gender, age, race, education, smoking status, alcohol drinking frequency, hypertension diabetes physical activity level, water intake, levels calcium, cholesterol, uric acid. Results A total 19,225 included. weighted prevalence was 11.1%. logistic showed a dose–response relationship METS-IR [odds ratio (OR) = 1.02, 95% confidence interval (CI) (1.01, 1.04), p < 0.01]. similar observed TyG-BMI full [OR 1.0, CI (1.0, 1.01), 0.001]. Sex-stratified analyses revealed that nephrolithiasis 1.03, 1.05), 0.01], 1.01, <0.001] significant among male fully adjusted model. Moreover, found 1.06), 0.05] diabetic adjustment. Furthermore, potential nonlinear other (i.e., TG/HDL-C, VAI, HOMA-IR) disease. Conclusion Higher associated with higher nephrolithiasis. Future investigations are required identify role progress formation propose prevention measures health guidelines.
Язык: Английский
Процитировано
3
Journal of Dermatological Treatment, Год журнала: 2024, Номер 35(1)
Опубликована: Июль 16, 2024
Psoriasis is a prevalent skin disease affecting approximately 1%-3% of the population and imposes significant medical, social economic burdens. involves multiple organs often complicated with obesity, diabetes, dyslipidemia, hypertension. Because benefits lipid-lowering agents antidiabetic medications for psoriasis, metabolic abnormalities possibly play pathogenic role in psoriasis.
Язык: Английский
Процитировано
2
Clinical Reviews in Allergy & Immunology, Год журнала: 2024, Номер 66(3), С. 294 - 315
Опубликована: Июль 2, 2024
Язык: Английский
Процитировано
2
Diagnostics, Год журнала: 2024, Номер 14(24), С. 2887 - 2887
Опубликована: Дек. 23, 2024
Background/Objectives: Psoriasis is a chronic dermatological condition with systemic implications, especially metabolic syndrome (MS). This study evaluated the vicious cycle where obesity and MS exacerbate inflammation that complicates efficacy of psoriasis therapies by examining PASI score over one-year period. Patients were classified into two subgroups: those alone (PSO) both (PSO-MS). Methods: A total 150 patients, half whom also concomitantly presented syndrome, received biologic comprising anti-IL-17, anti-IL-23, anti-TNF-a, or methotrexate, scores assessed at baseline 3, 6, 12 months. Results: All treatments showed significant reductions in PASI; however, patients PSO more marked than PSO-MS group. Anti-IL-17 produced greatest sustained long-term improvements, whereas anti-IL-23 prompt early improvements. Increases BMI leptin concentrations associated modest rate reduction score, underlining impact dysfunction on treatment efficacy. Conclusions: highlights importance managing comorbidities such as psoriasis, interplay between health further therapeutic outcomes.
Язык: Английский
Процитировано
1
British Journal of Dermatology, Год журнала: 2024, Номер 191(4), С. 486 - 487
Опубликована: Май 13, 2024
Journal Article Accepted manuscript Insulin resistance and psoriasis Get access Shirley P Parraga, Parraga Wake Forest University School of Medicine, Winston-Salem, NC, USA https://orcid.org/0009-0002-1835-1311 Search for other works by this author on: Oxford Academic Google Scholar Steven R Feldman USACenter Dermatology Research, Department Dermatology, USADepartment Pathology, Social Sciences & Health Policy, Corresponding author: R. Feldman, Email:[email protected] https://orcid.org/0000-0002-0090-6289 British ljae199, https://doi.org/10.1093/bjd/ljae199 Published: 13 May 2024 history Received: 30 April Accepted: 09
Язык: Английский
Процитировано
0
Journal of the European Academy of Dermatology and Venereology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 9, 2024
The data that support the findings of this study are available from corresponding author upon reasonable request.
Язык: Английский
Процитировано
0